Keywords: paladin, licenses, canadian, rights, depocyt, skyepharma, granted
Paladin licenses Canadian rights to DepoCyt
Article | 10 July 2000
SkyePharma has granted exclusive marketing and distribution rights toDepoCyt (depot cytarabine), its treatment for lymphomatous or neoplastic meningitis, to Paladin ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
